Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 3/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327899 | 0.84 | ALDH1A1 (0.75) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2390136 | 0.81 | ALDH1A1 (0.62) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2389057 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2386234 | 0.80 | BPTF (0.55) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2386636 | 0.80 | USP2 (0.51) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2386841 | 0.77 | USP2 (0.48) | ALDH1A1LMNATSHRHTTNPSR1 | |
| SCHEMBL2390198 | 0.76 | EPHX1 (0.53) | ALDH1A1LMNASRD5A2MEN1KMT2A | |
| SCHEMBL23610369 | 0.76 | KDM4E (0.71) | ALDH1A1LMNATSHRSMN1; SMN2SRD5A2 | |
| SCHEMBL17737082 | 0.76 | KDM4E (0.71) | ALDH1A1LMNATSHRSMN1; SMN2SRD5A2 | |
| SCHEMBL15876506 | 0.76 | SRD5A2 (0.50) | ALDH1A1LMNATSHRHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4257/4885LMNA 2607/4885TSHR 3724/4885 |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4257/4885LMNA 2607/4885TSHR 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.